Ten novel mutations were introduced into the Zp promoter to test the role of sequences outside the established transcription factor-binding sites in Epstein-Barr virus (EBV) reactivation. Most of these had only small effects, but mutations in the ZID site were shown to reduce Zp activity strongly at early times after induction by anti-immunoglobulin (anti-Ig). The binding of MEF2 transcription factor to ZID was characterized in detail and linked functionally to Zp promoter activity. The presence of XBP-1s, the active form of XBP-1, after administration of anti-Ig to Akata Burkitt's lymphoma cells is consistent with a role for this factor in reactivation of the EBV lytic cycle, although signalling through MEF2D was quantitatively much more significant in activation of Zp. Silencing of Zp during latency is thought to be primarily a consequence of a repressive chromatin structure on Zp, and this aspect of Zp regulation can be observed in the Akata genome through protection of Zp from activation by BZLF1 in the absence of signalling from the B-cell receptor.
INTRODUCTION
Reactivation of Epstein-Barr virus (EBV) from latency involves the induction of two viral transcription factors, BZLF1 (also known as Zta and ZEBRA) and BRLF1 (also known as Rta). These two proteins can cooperate to induce about 25 EBV early genes, which are sufficient to achieve replication of the viral DNA. Subsequent late gene expression and packaging of the replicated DNA eventually lead to production of new virus particles. The current model for the in vivo life cycle of EBV in healthy infected people envisages long-term persistence of EBV in a small proportion of the memory B-cell population (ThorleyLawson et al., 2008) . Fractionation of blood from EBV carriers revealed that markers of EBV lytic replication can be found in plasma cells (Laichalk & Thorley-Lawson, 2005) , suggesting that physiological signals for EBV reactivation from latency are likely to be linked to the process by which memory cells may give rise to plasma cells, which occurs in response to recognition of cognate antigen by the memory cell. The cell transcription factor XBP-1 plays a key role in the production of plasma cells (Iwakoshi et al., 2003; Reimold et al., 2001) ; using a myeloma cell line as a model of plasma cells, XBP-1 was found to contribute to regulation of the activity of the Zp promoter, from which BZLF1 is expressed (Sun & ThorleyLawson, 2007) . XBP-1 was also shown to cooperate with protein kinase D [which can inactivate histone deacetylases (HDACs)] in a transfection assay to activate Zp in an epithelial cell line and in an EBV lymphoblastoid cell line (Bhende et al., 2007) . In addition to its role in cell differentiation, XBP-1 acts as part of the unfolded protein response; activation of XBP-1 occurs by cytoplasmic splicing of its mRNA by IRE1, which removes 26 nt and creates a novel reading frame that can be translated to produce the active XBP-1s protein (Calfon et al., 2002) . However, activation of XBP-1 in B-cell development is thought to be a differentiation-dependent event and not simply the result of an unfolded protein response caused by abundant synthesis of immunoglobulin (Ig) (Hu et al., 2009 ).
A convenient model system for studying the process of EBV reactivation from latency to the lytic cycle is provided by the Akata Burkitt's lymphoma cell line (Takada & Ono, 1989) . Cross-linking the B-cell receptor (BCR) on the surface of these cells with an antibody to IgG mimics the signalling that would occur in the cells if cognate antigen were to bind to the BCR, and leads to a rapid reactivation of Zp and the EBV lytic cycle. The rapidity and synchrony of the reactivation that occurs in the 10-20 % of the Akata cell population that switches its EBV into the lytic cycle make this system suitable for studying the time course of events that may lead to reactivation (Bryant & Farrell, 2002) . By cloning the entire BZLF1 gene (including the Zp promoter) onto a plasmid containing the EBV oriP replication origin and stably establishing the plasmid as an episome in Akata cells, we previously showed that regulation of Zp on the plasmid closely mirrors that of Zp in its natural location in the EBV genome in Akata cells (Jenkins et al., 2000) . Quantitative measurement of Zp activity by linking Zp to a luciferase reporter in such plasmids allowed mapping of promoter sequences within Zp, revealing effects on the time course of Zp induction (Binné et al., 2002) . Comparison of activity of Zp and Rp (the promoter for BRLF1) in an EBV-negative clone of Akata cells showed that signal transduction from the BCR directly activates Zp but not Rp, clearly indicating that the induction of Zp is the first event in reactivation of EBV in this system (Amon et al., 2004) . Our previous mapping (Binné et al., 2002) of promoter elements in Zp using this system largely focused on the ZI, ZII and ZIII Zp elements that were originally identified by footprinting analysis of Zp and testing the response of Zp to induction by TPA (12-O-tetradecanoylphorbol-13-acetate) (Flemington & Speck, 1990) . Factors bound to the ZI, ZII and ZIII elements all play a positive role in Zp activation, but the factor bound to the additional ZV element normally represses Zp activity (Kraus et al., 2001; Yu et al., 2007) .
Mechanisms involving transcription factor activation, changes in DNA methylation and chromatin modification have all been proposed for the control of the EBV lytic cycle. In our previous investigation of the kinetics of reactivation of Zp in Akata cells (Bryant & Farrell, 2002) , we observed dephosphorylation of the MEF2D transcription factor (which is bound to the ZI elements) within 5 min of BCR cross-linking, and increased expression of BZLF1 protein within 30 min. Dephosphorylation of MEF2D mediates promoter activation and we already investigated the roles of the ZIA, B and C sites in Zp activation in Akata cells (Binné et al., 2002) . A fourth ZI site, known as ZID, has not previously been characterized in such detail, and the ZID site is adjacent to part of the proposed binding site for XBP-1 in Zp. In this paper, we test additional sequences in the Zp promoter for contribution to Zp regulation and show that the ZID element is required for the early phase of Zp induction. By mapping ZID accurately and testing additional mutations in the two consensus XBP-1-binding elements, we distinguish the contributions of the MEF2D-and XBP-1-binding sites to reactivation of Zp.
RESULTS
Additional sequences in the Zp promoter required for activation in response to BCR cross-linking Our previous studies indicated that all of the sequences required for efficient Zp reactivation lie within the 21 to 2226 bp Zp promoter (Jenkins et al., 2000) . As our earlier mutagenesis of the Zp promoter was confined to the previously reported ZI, ZII, ZIII and ZV elements in the 21 to 2226 region, we made further novel mutations in the gaps between those elements to search for additional sequences that might be important in Zp function. These seven mutations are illustrated in Fig. 1(a) and are labelled a-g. As before (Amon et al., 2004; Binné et al., 2002) , luciferase reporter oriP plasmids containing the mutations were transfected into EBV-positive Akata cells, and multiple independent cell lines were selected for each mutation. For each mutation, three cell lines that gave a similar fraction of cells induced into the lytic cycle by antiIg and had similar copy numbers of the oriP plasmid were chosen. These cell lines were assayed in duplicate for luciferase over a time course after anti-Ig induction. The mean of the six results for each data point (after normalization for the small variations in plasmid copy number and percentage of cells induced) is shown in Fig. 1(b, c) . All of the mutations except for g caused some reduction of luciferase reporter activity after 12 h, but some of the effects were slight; we particularly focused on those that gave large reductions in activity in the first 2-4 h, as these would be relevant to the early events that lead to Zp activation. Mutations b, d and f reproducibly caused substantial reductions in Zp luciferase activity 2-4 h after anti-Ig treatment. Of these three, the sequence modified by mutation d was of particular interest, as it gave the largest reduction in luciferase activity and lay within a region previously defined as ZID, but was also close to part of the consensus XBP-1-binding site. ZID has not been characterized in as much detail as the other ZI sites (ZIA and ZIB are known to bind MEF2D and to be essential for activation of Zp). No factors binding to sites b or f could be detected by electrophoretic mobility-shift assay (EMSA) (data not shown), so they have not been followed up further at this stage. Mutation d caused an 80 % reduction in Zp luciferase activity compared with wild-type Zp 2 h after addition of anti-Ig.
Mapping the MEF2D-binding site within the ZID element
In order to clarify the roles of MEF2D and XBP-1 in the ZID-XBP-1 (260 to 290; Fig. 1a ) part of the Zp promoter, we accurately defined the transcription factor binding to the ZID element and compared the effects of mutations in the two components of the XBP-1-binding site with mutation of ZID. Inspection of the ZID site showed that the sequence contained the perfect palindrome CTAAATTTAG, a possible indication of the binding site of a homodimeric protein. We therefore tested doublestranded (ds) oligonucleotides containing 20 nt of EBV DNA centred on this palindromic sequence in an EMSA with nuclear extracts from Akata cells. Complex formation was readily detected and the complex was entirely supershifted with an antibody that binds to all MEF2 isoforms ( Fig. 2a) , indicating the presence of MEF2 protein in the complex. As noted previously for ZIA/B, ZID-MEF2 complex formation appeared to be the same in the EMSA with or without anti-Ig treatment of the Akata cells (Fig. 2b) . Specificity of the MEF2 complex was confirmed further by showing that it was efficiently competed with an excess of the same ds oligonucleotide, but not by one of different sequence or by the mutant d oligonucleotide (Fig. 2a, b) . A competition assay was used to map the ZID nucleotides required for complex formation by testing the ability of a panel of non-radioactive ZID mutant ds oligonucleotides to compete the binding of Akata nuclear extract to the radioactively labelled wild-type ZID site in the EMSA (Fig. 2c-f ). All of the nucleotides were mutated as pairs and positions 6-15 were mutated individually. The results show that nt 7-14 (sequence TAAATTTA) is the core sequence required for complex formation. A slight additional contribution of the C(6) and G(15) nucleotides is also detectable in the 6+15 double mutant (Fig. 2f) . To relate the factor-binding site defined in the EMSA to the transcription effects in the luciferase reporter assay, key informative mutants in ZID were then tested by luciferase reporter assay. Mutations d, 16/17 and 7/14 were made in the oriP luciferase Zp reporter plasmids, which were transfected into Akata cells and multiple independent transfected cell lines were established. As described earlier, these were tested for luciferase induction after BCR crosslinking with anti-Ig. The results are shown in Fig. 3(a) . As predicted, mutation of residues within the ZID MEF2D-binding site greatly reduced the early activation of the Zp promoter, but mutation of residues just outside the MEF2D-binding site had little effect, confirming the role of this MEF2D-binding site in Zp induction in Akata cells.
Effect of mutation of consensus XBP-1-binding sites
Two parts of the proposed XBP-1-binding site of Zp were described previously (Sun & Thorley-Lawson, 2007) and are underlined in Fig. 3(a) . In a previous study, we had already mutated one of these XBP-1 consensus sequences (mutation ZII) (Binné et al., 2002) and shown that this mutation delays activation of Zp. The other consensus XBP-1 site closer to ZID had no detectable XBP-1 binding in myeloma cell extracts (Sun & Thorley-Lawson, 2007) , but this part of the Zp sequence (marked 'KSHV' in Fig. 3a) is, interestingly, identical to the XBP-1 site mapped in the promoter for the Rta gene of Kaposi's sarcoma-associated herpesvirus (KSHV) (Dalton-Griffin et al., 2009) . We therefore introduced two separate mutations into this part of the sequence and tested the effects in stably transfected Akata cell assays. Mutation i caused a 50 % reduction in early promoter activity (Fig. 3c) . Mutation h, which converts the CG sequence to AA, gave a modest reduction in Zp promoter activity but, even at early times, .50 % of the Zp activity remained (Fig. 3c) . The effects of mutation of these potential XBP-1 sites and the splicing of XBP-1 early after BCR activation are both consistent with a role for XBP-1 in the lytic reactivation of Akata cells, but the reduction in promoter activation caused by mutations in the consensus XBP-1 region is not as severe as that caused by mutation of, for example, the ZIA/B MEF2D-binding sites.
To test whether the active form of XBP-1 might be present, Akata cells were treated with anti-Ig and samples were taken at various times for RNA extraction. An RT-PCR assay was used to distinguish the spliced form of XBP-1 RNA, which corresponds to activated XBP-1s. The results show the presence of XBP-1s RNA 10-30 min after addition of anti-Ig (Fig. 4) . Activated XBP-1 was also present in EBV-negative Akata cells treated with anti-Ig (not shown) but, in different experiments, the extent of induction was variable and a delayed induction of XBP-1s RNA also occurred in response to anti-IgM (data not shown). It therefore appears that the active spliced form of XBP-1 is present during the time course of Zp induction in Akata cells, suggesting that XBP-1 could play a role in regulation of Zp in Akata cells, but it is not clear whether there is specific signalling from the BCR that activates XBP-1 in this system.
Functional assay for repression of Zp in latency
Although BZLF1 and BRLF1 both play key roles in EBV reactivation, we showed previously that induction of BZLF1 via Zp is the first event in reactivation in Akata cells in response to anti-Ig treatment (Amon et al., 2004) . Promoter methylation has been considered as a mechanism for maintenance of latency in EBV. The CpG dinucleotide mutated to AA in mutant h (Fig. 3a) happens to be the only CpG sequence in the entire 2226 Zp promoter and we noted previously that correct Zp regulation appears to occur on the oriP plasmids in the absence of any detectable CpG methylation of this site in the plasmids (Jenkins et al., 2000) . Consistent with this, there was little change in the constitutive activity of the Zp promoter when potential methylation was prevented at this site by mutation h (Fig. 3c) .
The concept that a repressive chromatin structure at Zp prevents BZLF1 gene expression during latency derives originally from the observation that transfection of a BZLF1 expression vector into Raji cells activates early gene expression, but does not induce the endogenous BZLF1 gene (Chevallier-Greco et al., 1986) . Later chromatin immunoprecipitation data directly showed a switch from deacetylated histone H4 to acetylated histone H4 at Zp during activation of the Akata Zp promoter in response to anti-Ig treatment of the cells (Jenkins et al., 2000) , and MEF2 was shown to recruit class II HDAC to Zp (Gruffat et al., 2002) . Phosphorylated MEF2D present during latency recruits HDACs, but dephosphorylated MEF2D binds histone acetyltransferase. The ability of an HDAC inhibitor to specifically overcome the inhibition of anti-Ig induction of Zp caused by mutation of the MEF2D-binding site in ZIA or B thus also supports the notion that transcription factors create a repressive chromatin structure on the Akata Zp region during latency (Jenkins et al., 2000) . To test the phenomenon of Zp repression on the Akata EBV genome more directly, we created an EBV-positive Akata cell line constitutively expressing a fusion protein of BZLF1 with part of the oestrogen receptor. This ZHT protein (Johannsen et al., 2004 ) is inactive until 4-hydroxytamoxifen (4HT) is added to the medium, whereupon it enters the cell nucleus and acts as BZLF1, efficiently inducing the EBV lytic cycle. The ZHT fusion protein is larger than Akata BZLF1, so they can be distinguished readily in Western blots of SDS-PAGE gels (Fig. 5) . In the Akata ZHT cells, it was noticeable that, although treatment with anti-Ig caused the normal rapid activation of BZLF1 and then induction of early genes such as BMRF1, activation of ZHT with 4HT caused a similar induction of the delayed-early gene BMRF1, but induction of the endogenous BZLF1 was greatly reduced (Fig. 5) , consistent with repression of Zp during latency protecting the promoter until signal transduction from the BCR causes specific activation.
DISCUSSION MEF2 binding and functional role of ZID
Previous studies of the ZID element had given conflicting indications of its role in Zp activation. When three copies of ZID and one copy of ZII were cloned upstream of a minimal b-globin promoter, this conferred a strong response to TPA induction when the reporter plasmid was transfected into DG75 cells (Borras et al., 1996) . Deletion analysis using transient transfection of a Zp reporter plasmid into Ramos cells showed little effect of ZID on the anti-Ig-dependent activation of the Zp promoter (Daibata et al., 1994) , and mutation of ZID had little effect on the response of a Zp reporter plasmid to VP16-HDAC4 transfected into DG75 cells (Gruffat et al., 2002) . Our   Fig. 4 . AK2003 cells were treated with anti-IgG and harvested at the time points indicated. RT-PCR amplification across the XBP-1 intron produces a 249 bp amplicon from XBP-1u mRNA and a 223 bp amplicon from XBP-1s mRNA. PstI digests the XBP-1u amplicon. As a positive control, cells were treated with 2 mM dithiothreitol (DTT) for 1 h to induce the unfolded protein response and XBP-1s expression. Samples were also analysed by RT-PCR for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a control. preliminary study using the Akata system showed an effect of mutating ZID in some experiments, but not others (Jenkins et al., 2000) . Our new results clearly show the importance of ZID in the early time course of Zp activation; the very late time points analysed by Jenkins et al. (2000) may explain those variable results. We have accurately mapped the MEF2-binding site in ZID to the palindromic sequence CTAAATTTAG, although the C and G nucleotides made only a small contribution. The core TAAATTTA is similar in sequence to the other MEFbinding sites ZIA, B and C.
Role of XBP-1
Previous studies of the effect of BCR cross-linking on XBP-1 activation in primary splenic B cells (Yan et al., 2008) or in a mouse B lymphoma cell line (Skalet et al., 2005) had analysed time points after 12-24 h, much later than the signal transduction that causes EBV reactivation in Akata cells. The spliced form of XBP-1 was consistently present in Akata cells treated with anti-Ig and, in some experiments, was induced in a time course coinciding with the induction of Zp (Fig. 4a) . The partial effects of mutating the XBP-1 site in reporter assays are consistent with a modest contribution of XBP-1 to Zp activation in B cells that has been reported previously (Bhende et al., 2007) . Knockout mouse studies indicate a role for XBP-1 in BCR function in vivo (Hu et al., 2009 ), but our extensive attempts (not shown) to test the role of XBP-1 in Zp activation by knockdown using small interfering RNA or short hairpin RNA approaches in Akata cells gave inconclusive results. XBP-1 may thus be involved in Zp activation, but signalling to MEF2D is faster and effects of mutating the MEF2D sites are much greater, so they seem to be more important in the response to BCR cross-linking in this system. In vivo, the relative importance of the two effects might be different.
Functional assay for repression of Zp in latency
Zp is clearly the first EBV promoter to respond to signalling from the BCR (Amon et al., 2004 ) and it appears that many of the transcription factors required for Zp induction are already bound to Zp during latency (Flemington et al., 1992) , but in an inactive state. Modifications to transcription factors that bind to Zp (Bryant & Farrell, 2002) and changes in histone acetylation at Zp that occur in response to anti-Ig treatment of Akata cells are physical measures of the repression of Zp by chromatin structure during EBV latency. Methylation of Zp promoter sequences does not seem to be a major mechanism by which latent inactivity of Zp is maintained, because there is only one CpG in the Zp promoter and it is largely unmethylated during latency (Binné et al., 2002) . Also, mutation of this CpG had very little effect on the constitutive activity of Zp (Fig. 3c) . Instead, it appears to be a repressive chromatin structure that keeps Zp inactive; one method by which the effects of that repressive chromatin structure at Zp can be observed functionally is through the way in which it makes Zp inaccessible to the auto-activation effects of BZLF1 prior to Zp being unlocked by BCR signal transduction to MEF2D. In this paper, we have now created a system using the ZHT fusion protein (Fig. 5) to study that phenomenon in Akata cells. This system may therefore now provide a functional assay to investigate further the precise biochemical mechanisms by which Zp is kept inactive during latency, but is induced strongly in response to BCR signalling.
METHODS
Cell culture, transfection and induction of the lytic cycle. The Akata (AK2003) and B95-8 ZHT cell lines were grown in RPMI 1640 (Gibco-BRL) supplemented with 200 U penicillin ml 21 , 200 U streptomycin ml 21 and 10 % (v/v) heat-inactivated Serum Supreme (BioWhittaker). Akata cells had been single-cell-cloned to generate the EBV-positive AK2003 cell line (Bryant & Farrell, 2002) . Plasmids were electroporated into Akata cells as described previously (Jenkins et al., 2000) . Induction of the lytic cycle was performed with goat antihuman IgG antibody (Sigma) at a final concentration of 5 mg ml
21
. The ZHT fusion protein was activated by treating B95-8 ZHT cells with 0.2 mM 4HT (Sigma).
Luciferase assays. Cells were harvested by centrifugation at 1500 g for 5 min, washed with ice-cold PBS and lysed in 100 ml 16 reporter lysis buffer (Promega) for 10 min at room temperature. Cell debris was removed by centrifugation. A 20 ml sample of supernatant was assayed for 10 s on a Berthold Autolumat luminometer with 100 ml luciferase assay substrate (Promega). For each plasmid, triplicate cell lines were assayed in duplicate. Luciferase data were normalized for plasmid copy number by Southern blot analysis, for protein concentration by using Bradford assays and for the proportion of cells induced into the lytic cycle by FACS (fluorescence-activated cellsorting) analysis, as described previously (Binné et al., 2002) .
Site-directed mutagenesis. The pHEBo : Zp-wt-luc reporter plasmid was described previously (Binné et al., 2002) . DNA mutations were introduced by using a QuikChange Site-Directed Mutagenesis kit (Stratagene). Sets of complementary primers were designed with the required mutations, flanked by unmodified nucleotide sequence. The mutations are illustrated in Figs 1(a) and 3(a).
XBP-1 assays. Total RNA was extracted from 5610 6 cells with 1 ml TRIzol reagent (Invitrogen). RNA samples were digested with RQ1 RNase-free DNase (Promega). cDNA was synthesized by using a Protoscript First Strand cDNA Synthesis kit (New England Biolabs). DNA fragments were amplified across the XBP-1 splice junction as described previously (Wilson et al., 2007) . PCR products were digested with PstI restriction enzyme (New England Biolabs) overnight at 37 uC prior to electrophoresis.
Western blotting. Cell samples were lysed for 15 min on ice in 2 vols RIPA lysis buffer [150 mM NaCl, 1 % (v/v) Nonidet-P40, 0.5 % (v/v) deoxycholic acid, 0.1 % (w/v) SDS, 50 mM Tris/HCl, pH 8.0] supplemented with 1 mM PMSF and Complete protease inhibitors (Roche). Samples were centrifuged at 16 000 g for 5 min to pellet cell debris and the supernatant was harvested. Proteins were fractionated by SDS-PAGE and transferred to nitrocellulose membranes.
After blocking for 1 h at room temperature in 5 % milk powder made up in PBS/0.1 % Tween 20, membranes were incubated with the primary antibody diluted in blocking buffer [for BZLF1, BZ-1 diluted 1 : 500; for BMRF1, EA-D (Chemicon) diluted 1 : 5000; for BdRF1, VCA-p40 diluted 1 : 1000; for actin, anti-b-actin clone AC-15 (Sigma) diluted 1 : 20 000] at 4 uC overnight. Sheep anti-mouse-horseradish peroxidase conjugate (GE Healthcare) was used as a secondary antibody at a dilution of 1 : 2000 and complexes were visualized by using ECL Western blotting detection reagents (Amersham).
EMSA. The ds ZID oligonucleotide (sense strand, CACACCTAAA-TTTAGCACGT) was end-labelled with T4 polynucleotide kinase (New England Biolabs). Nuclear extracts were prepared as described previously (Bryant & Farrell, 2002) and protein concentrations were determined by using the Bio-Rad DC protein assay. Reactions were carried out as described previously (Bryant & Farrell, 2002) except that 10 mg extract and 4 ng probe DNA were used per reaction. For competitions, binding was competed with a 100-fold excess of competitor oligonucleotides. ZID mutant oligonucleotides are illustrated in Fig. 3 . When anti-MEF2 antibody (MEF2 C-21; Santa Cruz) was used to supershift complexes, 1 ml was added prior to addition of the labelled probe. Samples were electrophoresed on 4 % polyacrylamide gels in 0.56 Tris/borate EDTA and results were detected on a phosphoimager.
Plasmids. Puro-OriP : ZHT was made by cloning a SalI fragment from pCDNA3-ZHT (Johannsen et al., 2004) , containing the cytomegalovirus immediate-early promoter and the BZLF1-HT gene, into the XhoI site of the puro-oriP plasmid (Amon et al., 2004) , choosing the insert orientation that placed ZHT transcription in the same direction as that for the puromycin-resistance gene. pCDNA3-ZHT was kindly provided by E. Kieff (Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA).
